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Background: Patients with familial adenomatous polyposis (FAP) are at increased risk for the development of
colorectal cancer. Surgery and chemoprevention are the most effective means to prevent cancer development.
Thymoquinone (TQ) is considered the main compound of the volatile Nigella sativa seed oil and has been reported
to possess anticarcinogenic properties. In this study we evaluated the chemopreventive properties of TQ in a
mouse model of FAP.
Methods: APCMin mice were fed with chow containing 37.5 mg/kg or 375 mg/kg TQ for 12 weeks. H&E stained
intestine tissue sections were assessed for tumor number, localization, size, and grade. Immunohistochemistry for
β-catenin, c-myc, Ki-67 and TUNEL-staining was performed to investigate TQ’s effect on major colorectal cancer
pathways. TQ’s impact on GSK-3β and β-catenin were studied in RKO cells.
Results: 375 mg/kg but not 37.5 mg/kg TQ decreased the number of large polyps in the small intestine of APCMin
mice. TQ induced apoptosis in the neoplastic tissue but not in the normal mucosa. Furthermore, upon TQ
treatment, β-catenin was retained at the membrane and c-myc decreased in the nucleus, which was associated
with a reduced cell proliferation in the villi. In vitro, TQ activated GSK-3β, which induced membranous localization
of β-catenin and reduced nuclear c-myc expression.
Conclusions: In summary, TQ interferes with polyp progression in ApcMin mice through induction of tumor-cell
specific apoptosis and by modulating Wnt signaling through activation of GSK-3β. Nigella sativa oil (or TQ) might
be useful as nutritional supplement to complement surgery and chemoprevention in FAP.
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In developed countries, colorectal cancer is one of the
most common types of cancer, ranking 2nd and 3rd in
women and men respectively. The lifetime risk for colo-
rectal cancer development in the general population is
approximately 6% and is responsible for about 8% of all
cancer deaths worldwide [1]. Certain familial syndromes
are at increased risk for the development of colorectal
cancer. This is about 80% in hereditary nonpolyposis* Correspondence: christoph.gasche@meduniwien.ac.at
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reproduction in any medium, provided the orcolorectal cancer and almost 100% in familial adenoma-
tous polyposis (FAP) [2].
FAP is an autosomal dominantly inherited disease
caused by a germline mutation of the adenomatous po-
lyposis coli gene (APC) located on chromosome 5q21
[3,4]. It is characterized by the development of numer-
ous, predominantly large intestinal adenomatous polyps,
ultimately leading to colorectal cancer [2]. Besides endo-
scopic surveillance and prophylactic surgery, chemopre-
vention is the most effective means to repress cancer
development in FAP. Inhibition of polyp progression
improves tumor outcome, thereby prolonging survival
in FAP patients. The protective effect of non-steroidal
anti-inflammatory drugs (NSAIDs) such as aspirin [5],
sulindac [6,7] and the selective cyclooxygenase-2 inhibitord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Some also reduce rectal polyp burden after colectomy
with ileorectal anastomosis [6]. Celecoxib was shown to
be beneficial against the duodenal tumor burden [9].
However, a chemoprevention study dealing with genotypi-
cally but not phenotypically affected patients treated with
sulindac failed to show prevention of primary adenoma
development [7]. Unfortunately, these drugs are associated
with gastrointestinal (bleeding, ulceration) and cardio-
vascular side effects (thromboembolic events and heart
failure) in the long-term [10-12].
In consideration of such side effects, the use of natu-
ral substances such as curcumin, eicosapentaenoic acid,
apple polyphenols, capsaicin, or thymoquinone (TQ) for
chemoprevention is emerging [13-15]. TQ is the main
active component of the volatile Nigella sativa (black
cumin) seed oil, which is used as a spice in countries
with low incidence of colorectal cancer such as Egypt,
Pakistan, or India. Traditional medicine has utilized
its anti-inflammatory, antioxidant, and anti-carcinogenic
properties, supporting TQ as a promising dietary che-
mopreventive agent [16]. In vitro studies indicate that
TQ inhibits tumor cell proliferation in various cancers
[17-19], including colorectal cancer [20,21]. TQ induces
a G1 cell cycle arrest, increases p53 and p21WAF1 pro-
tein levels, induces apoptosis in a dose- and time-
dependent manner, and reduces Bcl-2 protein in
HCT116. Further actions of TQ include inhibition of
angiogenesis, endothelial cell migration, invasion, and
tube formation as demonstrated in HUVECs [18]. In
vivo weekly i.p. injections of 5mg/kgbw TQ reduced the
number and size of aberrant crypt foci and tumor multi-
plicity in a chemically-induced colorectal cancer mouse
model. The suppression of tumor development was sus-
tainable, as treatment with TQ resulted in a reduction of
tumor number even after a 10-week discontinuation.
Furthermore, in a HCT116 cell xenograft model, a
3-times weekly i.p. injection of 20 mg/kg TQ reduced
the relative tumor size by 29% from 2.8 to 2.0 mm2 [20].
This study was designed to test the chemopreventive ef-
fect of TQ in ApcMin (APC, adenomatous polyposis coli;
Min, multiple intestinal neoplasia) mice, which best
resemble the FAP phenotype.
Results
TQ attenuates tumor growth in ApcMin mice
To evaluate the effect of TQ on polyp formation in the
APCMin mouse, 4–6 week old female and male animals
were randomly divided into 4 groups and treated over a
period of 12 weeks. Neither TQ nor piroxicam influen-
ced weight gain and food uptake (Additional file 1:
Figure S1). Mouse colonoscopy at week 9 demonstrated
a significant reduction of distal large intestinal polyps in
the TQ-low and the piroxicam group (p<0.05), witha trend also for TQ-high (p=0.124; Additional file 2:
Figure S2).
At 12 weeks mice were euthanized and intestinal Swiss
rolls were analyzed for tumor number, size (Additional
file 1: Figure S1C), and localization (colonic or small in-
testine). TQ-high decreased the number of large polyps
(>1mm) in the small intestine from 10 (95% CI 8–13) to
5 (2–8; p<0.05), while small and medium-sized polyps
were unchanged (Figure 1). Tumor multiplicity changed
minimally, from 34 (29–40) in untreated APCMin mice
and 38 (32–44) in TQ-low to 27 (21–33) in TQ-high
mice (p= 0.22; Additional file 2: Figure S2C). Piroxicam
decreased medium-sized polyps from 18 (14–22) to 4
(0–7), large polyps from 10 (8–13) to 0 (-3-3) and tumor
multiplicity from 34 (29–40) to 7 (1–13) as expected
(Figure 1). Colonic polyp numbers revealed no significant
differences between the treatment groups (Figure 1B). A
trend was observed for the reduction of colonic polyps
within the piroxicam and TQ-high treated groups. Adeno-
carcinoma formation in the small intestine, defined as
penetration of the muscularis mucosae, was found in 1
out of 13 mice in the TQ-low group and in 1 out of 16
mice in the TQ-high group (Additional file 1: Figure S1E).
TQ induces apoptosis in polyps of ApcMin mice
To ascertain the effect of TQ on apoptosis, TUNEL-
staining of Swiss rolls was performed. Apoptotic cells
were analyzed within polyps and normal mucosa of the
small intestine. The number of apoptotic cells increased
in the neoplastic but not in the normal tissue upon TQ
treatment (Figure 2). The average number of apoptotic
cells within polyps was 18±16 per FoV for untreated,
45±18 for TQ-low and 50±30 for TQ-high treated mice
(p<0.05 and p<0.01, respectively). However, this effect
was not observed in the piroxicam treated group (13±14
per FoV). These results suggest that TQ reduces polyp
growth through selective induction of apoptosis.
TQ reduces proliferation in the villi of ApcMin mice
Nuclear Ki-67 staining was assessed to investigate the ef-
fect of TQ on cell proliferation. The percentage of Ki-67
positive cells was scored in polyps, normal crypts and
villi of APCMin. Neither TQ nor piroxicam altered the
number of Ki-67 cells in polyps or crypt cells (Additional
file 3: Figure S3). In C57BL/6 wt mice Ki-67 positive
cells are specifically restricted to the crypt cells. In
APCMin mice, however, we observed nuclear Ki-67 stai-
ning also in cells of the intermediate zone of the villi. A
reduction of Ki-67 positive cells in TQ-high and to a
lesser extent also in TQ-low treated mice was observed.
The mean Ki-67 IRS in the villi was reduced from
4.8±1.6 to 4.0±1.7 in TQ-low and to 3.6±1.8 in TQ-high
(p<0.05) treated cells. Again piroxicam had no effect
(IRS 5.1±1.7).
Figure 1 TQ-high reduces large tumors in the small intestine (SI). Size distribution of polyps in the SI (A) and colon (B) of APCMin mice
(small <0.3 mm; medium: 0.3–1 mm; large: >1 mm). Bars show mean number (± SD) of SI or colonic polyps/mouse. TQ-high (n=16) but not
TQ-low (n=13) decreased the number of large polyps in the SI. Piroxicam (n=15) decreased the number of medium and large SI polyps. TQ-high
and piroxicam show a trend for reduction of colonic polyps (B) *p<0.05, ***p<0.001; ANOVA, Dunnett 2-sided. Representative H&E-stained Swiss
rolls from different treatment groups: untreated (C, n=17), TQ-high (D) and piroxicam (E). Arrows indicate SI polyps of different size.
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mice
We further analyzed nuclear c-myc expression, which is
highly abundant in proliferative tissue and necessary for
cell cycle progression [22]. TQ-low (p<0.001) and TQ-
high (p<0.01) treatment reduced nuclear c-myc pro-
tein in the polyps, an effect which was not observed
in piroxicam-treated mice (Figure 3).
TQ translocates β–catenin to the membrane in APCMin
polyps
As TQ influenced tumor size and and c-myc expression,
we considered how TQ may be implicated in the β–
catenin pathway. Loss of APC protein leads to a dere-
gulated WNT/β–catenin pathway, as APC is part of the
β–catenin destruction complex. Deregulated β–catenin
degradation leads to an accumulation of free β–catenin
and nuclear translocation. In the nucleus, β–catenin acts
as a transcription factor binding in a complex with
TCF/LEF to DNA enhancer sequences leading to the
upregulation of genes like the proto-oncogene c-myc[23]. A membranous, cytoplasmic, and nuclear IRS was
calculated for β–catenin in the normal mucosa, small and
large polyps. Remarkably, β–catenin was translocated to
the membrane in large polyps of TQ-high treated APCMin
mice (p<0.05; Figure 4). A trend towards this effect was
seen for small polyps as well (p=0.064). We found a simi-
lar trend for β–catenin shifting to the membrane in
piroxicam treated mice (p=0.094). No change in β–catenin
expression within the normal epithelium was identified,
except for a slight increase in cytoplasmic β–catenin levels
in TQ-low treated mice, an effect which was abrogated in
small and large polyps. To further investigate β-catenin
expression upon TQ treatment, we studied the poorly dif-
ferentiated colon cancer cell line RKO, which harbors wt
APC [24], wt p53 [25] and wt β-catenin alleles, the latter
being expressed at low levels [24]. Treatment with TQ
resulted in decreased nuclear β-catenin within 4 h and up
to 24 h (as shown by Western blot). In parallel, mem-
branous and cytoplasmic β-catenin increased at 4 h
(Figure 5A). In conclusion, TQ reduces nuclear β–catenin
and translocates β–catenin to the membrane.
Figure 2 TQ induces tumor-specific apoptosis in APCMin mice. TQ-low and TQ-high significantly increased the number of apoptotic cells
(by TUNEL assay) within SI polyps but not in the normal mucosa (A). Bar graphs display the mean number (± SD) of apoptotic cells per field of
view (FoV, n=12). *p<0.05, **p<0.01; by ANOVA (2-sided Dunnett); paired T-test was used to compare the normal mucosa to neoplastic cells
within each group (only significant for TQ-high). Representative images of normal mucosa (upper panel) and polyp tissue (lower panel) in
untreated (B), TQ-high (C, F), and piroxicam treated APCMin mice (D). DNase I treated positive control (E). DAPI (blue) and incorporated
fluorescein-12-dUTP (green) signals were imaged at 400x using a confocal fluorescence microscope (LSM 5 Exciter; analysis software: LSM image
examiner, Zeiss, Jena, Germany).
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cancer cells with various mutational backgrounds
To assess the effect of TQ on cell viability, MTT assays
were performed in different human colon cancer cell
lines (having various mutational backgrounds) and in
HCEC-1CT normal diploid human colon epithelial cells.
APC-truncated and p53-mutated cells (DLD1 and HT29)
are the most resistant to TQ (IC50: 196 μM and 160 μM,
respectively). LoVo, which has wt p53 and mutated APC,
was the most sensitive, having an IC50 value of 36
μM. In comparison, cells with wt p53 and wt APC
such as HCT116, RKO and HCEC-1CT were less af-
fected by TQ, with IC50 values of 118, 86 and 79 μM,
respectively (Additional file 4: Figure S4A). These re-
sults indicate that TQ’s effect on cell viability may be
influenced by the mutational status of APC and p53.
To provide further evidence that TQ induces cell apop-
tosis rather than cell cytostasis, RKO cells were incu-
bated with increasing TQ concentrations for 24 h and
Annexin V/PI staining was performed. Indeed, TQ
treatment led to a concentration dependent increasein apoptotic and dead cells measured by flow cytome-
try (Additional file 5: Figure S5).
TQ acts on the GSK-3β pathway
TQ was reported to inhibit proliferation and angioge-
nesis by suppressing ERK and AKT phosphorylation in
HUVECs [18]. In RKO, ERK1/2 and AKT1 are highly
phosphorylated. In our experiments, TQ did not have any
effect on the phosphorylation status of ERK1/2 (Thr202/
Tyr204) nor AKT1 (Ser473) from 30’ to 12h, despite suc-
cessful inhibition of phosphorylation of ERK1/2 by the
MEK1/2 inhibitor UO126 (Additional file 4: Figure S4C
and D). A well-known downstream target of the PI3K/
AKT pathway and, alternatively, the RAS/RAF/MEK/ERK
pathway, is the glycogen synthase kinase 3β (GSK-3β).
The activity of GSK-3β is inversely correlated with its
phosphorylation status at Ser9. When testing for GSK-3β
phosphorylation upon TQ treatment, we observed a re-
duction of p-GSK-3β. GSK-3β appears to be an important
molecular target of TQ, which may subsequently affect
the stability of c-myc (Figure 5).
Figure 3 TQ decreases nuclear c-myc protein in polyps of APCMin mice. IRS of nuclear c-myc expression from polyps (n=16) of untreated,
TQ-low, TQ-high, or piroxicam treated APCMin mice (n=4; A). ANOVA, Dunnett, 2-sided was used to compare the different treatment groups to
the untreated group; **p<0.01, ***p<0.001. Every dot in the graph represents a single polyp analyzed for nuclear c-myc intensity as follows: 0,
negative staining; 1+, weak staining; 2+, moderate staining. Treatment with TQ-low or TQ-high significantly decreased nuclear c-myc within the
polyps. Representative image for untreated (B) and TQ-high treated (C) mice. Image D shows the negative control sample without the primary
antibody (D). Magnification: 100× (left panel), 200× (right panel).
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Active GSK-3β is assumed to be an important kinase
phosphorylating c-myc on Thr58 for subsequent ubiqui-
tination by the F-box protein Fbw7 [26], a component of
the SCF-class ubiquitin ligase (E3) complex, and degra-
dation. Indeed, treatment with TQ reduces c-myc ex-
pression at 2 h and 24 h (Figure 5A-C). The subcellular
distribution of c-myc showed reduced expression of nu-
clear c-myc upon TQ treatment (Figure 5A), which is in
line with the reduced nuclear c-myc expression in polyps
of APCMin mice (Figure 3). To further support the medi-
ation of c-myc reduction at protein level, c-myc mRNA
was quantified. In fact, the expression of c-myc mRNA
was not altered upon TQ treatment (Additional file 4:
Figure S4B).
TQ reduces GSK-3β phosphorylation via inhibition of the
MEK1/2 pathway rather than PI3K
As a next step we verified if the reduced GSK-3β phos-
phorylation upon TQ treatment was dependent on the
PI3K pathway, which is upstream from GSK-3β. We
used the PI3K inhibitor LY294002 together with TQ to
test for synergistic or additive effects. Treatment withTQ and LY294002 for 2 h and 4 h reduced the levels of
GSK-3β phosphorylation in an additive manner (see also
Figure 5D, E, Table 1 and Methods section for statistical
explanation) indicating that TQ’s effect on GSK-3β phos-
phorylation is independent of PI3K. As expected, total
GSK-3β levels remained stable over time. Also, total
c-myc protein was reduced more effectively at the 4 h point
in time, if both substances have been added (Figure 5D).
We then investigated the RAS/RAF/MEK pathway,
which also influences GSK-3β Ser9 phosphorylation.
MEK1/2 inhibition with UO126 and concomitant incu-
bation with TQ did not show additional reduction of
GSK-3β phosphorylation (Figure 5E), assuming that both
compounds are utilizing the same pathway. As stated
above, pharmacological inhibition of MEK1/2 in RKO
cells resulted in an abrogation of p-ERK1/2 phosphory-
lation that was not seen on treatment with TQ. There-
fore, we assume that TQ carries out its function by
inhibiting another kinase in this pathway.
Discussion
In this study we demonstrate that TQ, the main active
component in the essential oil of Nigella sativa seeds,
Figure 4 β-catenin expression in untreated, TQ-low, TQ-high, or piroxicam treated APCMin mice (n=8). Membranous (A), cytoplasmic
(B), and nuclear (C) β-catenin IRSs were calculated for epithelial cells of the normal mucosa, small and large polyps. Bar graphs display mean
β-catenin IRSs ± SD. TQ-high treated mice (E) showed an increase in membranous β-catenin expression in large polyps (ANOVA, Dunnett,
2-sided, *p<0.05) and a trend for an increase in small polyps (p=0.064) when compared to untreated (D) APCMin mice. Membranous β-catenin
expression in piroxicam treated mice did not reach significance (p=0.094) due to a too small number of large polyps, although a membranous
relocalization of the protein was present as in the TQ-high treated mice. Cytoplasmic expression of β-catenin increased upon TQ-low and
TQ-high (p=0.064) treatment in the normal mucosa. Magnification: 40x (left panel) and 400x (right panel). Panel F shows the negative control
sample without the primary antibody (F).
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of APCMin mice. This effect was mainly due to induction
of tumor cell-specific apoptosis. In addition, we found a
shift of β-catenin to the membrane and a reduced nu-
clear c-myc expression in polyps. In RKO, TQ activates
GSK-3β, which in turn might mediate phosphorylation
and subsequent degradation of c-myc protein (model see
Figure 6).
Black cumin seed oil is commonly used in traditional
medicine and as a spice in countries with low prevalence
for colorectal cancer [16]. It has been described to inter-
fere with several tumor pathways. Gali-Muhtasib and
others showed that TQ reduces the number of aberrantcrypt foci and inhibits tumor growth in a 1,2-dimethyl-
hydrazine-induced and a xenograft colon carcinogenesis
mouse model, mainly by induction of apoptosis. Further-
more this group demonstrated that TQ decreases the in-
vasive potential of a mouse colorectal cancer cell line
[20]. Other publications showed that the antiproliferative
and apoptotic effects of TQ are either mediated by p53-
dependent or independent mechanisms. The former
could be shown for colorectal cancer cells, the latter
only for osteosarcoma cells [27] and a myeloblastic leu-
kemia cell line [28]. p53-null HCT116 cells were less
sensitive to TQ-induced growth arrest and apoptosis
compared to p53-wt HCT116 cells [21]. The reduced
Figure 5 Effect of TQ on β-catenin and the glycogen synthase kinase 3β (GSK-3β) pathway in RKO. Separating for membranous,
cytoplasmic and nuclear protein fractions showed reduction of nuclear β-catenin and c-myc upon 30 μM TQ for up to 24 h and a short term
increase of membranous and cytoplasmic β-catenin. α-tubulin is used as a total protein and cytoplasmic marker, fibrillarin as nuclear marker, and
Na-K-ATPase as membranous marker (A). TQ reduces the amount of p-GSK-3β Ser9, the inactive form of the protein, at concentrations of 10 and
30 μM, shown by Western blot (B) and fluorescence microscopy (C; top panel, green: p-GSK-3β, blue: DAPI; LSM 700). Total GSK-3β protein levels
are constant over time (B; C, bottom panel). Total c-myc levels were reduced at 30 μM TQ up to 24 h, an effect that was not seen for 10 μM (B).
30 μM TQ and 30 μM PI3K inhibitor LY294002 additively reduced the amount of p-GSK-3β in total protein lysates. 5 independent Western blots
had been carried out and the ratio of p-GSK3-3β levels and total GSK3-3β protein has been calculated with densitometry analysis (D, E and see
also Table 1 for the statistical calculations). Treatment with TQ increased total β-catenin protein but reduced the amount of c-myc protein (D).
Inhibition of MEK1/2 with 30 μM UO126 reduced p-GSK-3β, while concomitant incubation with TQ did not lead to an additive reduction of
p-GSK-3β (F).
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regulation of the DNA damage sensor CHK1, which is
normally transcriptionally repressed by p53 [29]. This is
in line with our observation that cells having functional
p53, such as LoVo, HCEC-1CT, RKO and HCT116,are more sensitive to TQ induced cell death compared
to cells with p53 mutations, as shown for DLD1 and
HT29. Also, we could confirm in our model that one
of the main chemopreventive pathways of TQ is the
cancer cell-specific induction of apoptosis which is
Table 1 GSK-3β dephosphorylation
Treatment Experiment Experiment 1-5
1 2 3 4 5 AVG of [1] -[2] (±SD)
DMSO 1.06 0.91 0.96
ut 1.00 1.00 1.00 1.00 1.00
2 h TQ 0.90 0.87 0.66 0.47
PI3K-inh. 0.69 0.84 0.86 0.57
[1] TQ + PI3K-inh. 0.61 0.47 0.46 0.41
[2] Multiplication of TQxPI3K-Inh. 0.61 0.73 0.56 0.27
Difference [1] -[2] at 2 h −0.01 −0.26 −0.10 0.15 −0.06 (±0.17)*
4 h TQ 0.93 1.07 0.76 0.92
PI3K inh. 0.67 1.04 0.64 0.69
[1] TQ + PI3K inh. 0.59 0.53 0.47 0.62
[2] Multiplication of TQxPI3K-Inh. 0.62 1.11 0.49 0.63
Difference [1] -[2] at 4 h −0.03 −0.59 −0.02 −0.01 −0.16 (±0.28)**
RKO cells were treated with TQ, PI3K inhibitor or with a combination of both substances for 2 h or 4 h to test for syngergistic or additive effects on the
dephosphorylation of GSK-3β. 5 different Western blots were performed and the relative ratios of p-GSK-3β and total GSK-3β protein levels were calculated using
the program Image J. Mathematically, when effects are measured as proportions, the additive effect of two substances is the multiplication of the two values
resulting from the single treatments. The mathematical product of both treatments is only minimally deviating from the actual values for the double treatment
resulting from the Western blots. The null-hypothesis of no mean difference cannot be rejected at either time point (T-test, p-value *0.56 (2 h) and **0.34 (4 h)).
While this result is in itself no proof of additivity, a closer inspection of the calculated differences shows that the assumption of additivity is indeed reasonable: In
experiments 1, 3 and 5 the differences are very close to zero. Experiments 2 and 5 show stronger deviations, however in opposite directions and the resulting
mean differences are close to zero for both time points.
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tive stress and subsequently H2AX phosphorylation in
HCT116 cells, which was diminished in p53−/− HCT116
[29]. The authors concluded that the changes in H2AX
expression and the increased apoptosis correlated with
enhanced mitochondrial ROS production. In addition










Figure 6 A model of TQ’s effect on colon cancer cells. In untreated col
(Ras-Raf-MEK, PI3K-AKT1, WNT), and thereby inactivated. This allows accumu
activation of Tcf/LEF-1. Thymoquinone (TQ) treatment reduces GSK-3β Ser9
relocalization of β-catenin to the membrane (green arrows) and reduction
subsequent degradation; blue arrow; ref. 37).observed that TQ reverses the Ki-67 positivity found in
the cells of the intermediate zone of APCMin villi. This
is indicative of lowered proliferation in the normal tis-
sue. However, the number of Ki-67 was not altered in
polyps. This result is in agreement with previous studies
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phorylation status of GSK-3β, an important kinase for
cell differentiation and apoptosis, showed reduced phos-
phorylation and activation of the protein. There is in-
creasing evidence that c-myc Thr58 is phosphorylated
by active GSK-3β, thereby regulating its stability by me-
diating Fbw7-driven turnover [26]. Enhanced GSK-3β
activity by TQ might lead to phosphorylation and sub-
sequent degradation of c-myc. The cause of reduced
Ser9 phosphorylation in RKO cells is still elusive. Con-
comitant treatment with TQ and the PI3K inhibitor
LY294002 leads to an additive reduction of p-GSK-3β,
assuming that, in colon cells, TQ does not utilize the
PI3K/AKT pathway, as shown for prostate cancer [18].
Instead, inhibition of MEK1/2 with UO126 reduced p-
ERK1/2 and p-GSK-3β levels and concomitant treatment
with TQ did not reveal an additive effect on GSK-3β
phosphorylation, indicating that TQ mediates its effect
over the RAS/RAF/MEK pathway rather than ERK1/2.
As shown in vivo and in vitro TQ leads to membranous
β-catenin translocation, which is probably also mediated
by GSK-3β activation. This is in line with a study con-
ducted by Li et. al. showing that active GSK-3β interacts
with MUC1, thereby releasing MUC1 bound β-catenin,
which then associates with membranous E-cadherin [30]
(Figure 6).
One shortcoming of the study is the limited effect of
TQ on tumor multiplicity. In this respect our results de-
viate from a chemically-induced colorectal cancer model
[20]. TQ may have less activity in genetically-driven can-
cer models such as the APCMin mouse than in chemically-
induced models. Another contributing factor might be
the administration route of TQ (as part of the chow
versus intraperitoneal injections). Also differences in
the mutational status of APC may partially explain
this phenomenon. We have therefore used RKO cells
(APC wt) for in vitro studies.
The TQ concentration in seeds is between 0.12 and
0.25% (w/v) [31,32]. In the essential oil, which is about
0.41 - 0.44% of the total seed, the TQ concentration is
between 28 - 57% [31]. The human equivalent dose of
375 mg/kg TQ in the diet corresponds to 3.6 mg/kg
body weight, resulting in a total amount of 219 mg for a
body weight of 60 kg [33]. Studies using TQ in H. pylori
infection [34] or diabetes [35] report an uptake of up to
3 g Nigella sativa seeds/day for one to three months,
respectively. Both studies report amelioration of the dis-
ease but no severe side effects or adverse effects on renal
or hepatic functions, respectively. Assuming a seeds con-
tent of 0.2% TQ, this results in an effective dose of 6 mg
TQ per day. In mice, no adverse effects except for a
decrease in glucose levels was observed with TQ con-
centrations up to 90 mg/kg body weight [36]. The cor-
responding concentration in our study was 45 mg/kgbody weight for TQ-high. Thus the concentrations used
are likely well tolerated without major toxicity. A dose
dependent decrease of GSH levels in vital organs was
found only with higher concentrations (2–3 g/kg, p.o.),
most probably due to formation of TQ conjugates with
GSH (glutathionyl-dihydrothymoquinone), which might
affect bioavailability as well as antioxidant properties of
TQ [36,37].
In summary, TQ interferes with polyp progression in
APCMin mice by inducing tumor cell-specific apoptosis
and by modulating Wnt signaling through GSK-3β acti-
vation, β-catenin translocation and reduction of nuclear
c-myc. TQ or Nigella sativa seed oil might be a useful
nutritional supplement to complement current chemo-
prevention in FAP.
Methods
Mice, genotyping, treatment, and colonoscopy
Heterozygous male C57BL/6J-ApcMin/J (APCMin) mice
(The Jackson Laboratory, Bar Harbor, ME) were bred
with wild-type female C57BL/6J mice. ApcMin mice har-
bor a nonsense mutation at nucleotide 2549 in the mur-
ine homolog of the human APC gene [38]. Genotyping
was performed from mouse tail DNA using primer-
introduced restriction analysis-polymerase chain reac-
tion with APC primers (APCfor: 5‘-TCT CGT TCT GAG
AAA GAC AGA AGC T-3‘; APCrev: 5‘-TGA TAC TTC
TTC CAA AGC TTT GGC TAT-3‘) and HindIII di-
gestion according to Musteanu et.al [39]. 4–6 week old
female and male APCMin mice were housed at the Insti-
tute of Biomedical Research (Medical University Vienna,
Vienna). Mice were kept under 12 hour light/dark cy-
cles. Chow and water were available ad libitum. Animals
were weighed weekly and the amount of food intake was
documented. All animal experiments were performed in
accordance with the Austrian and European law, defined
by the Good Scientific Practice guidelines of the Medi-
cal University Vienna (animal ethics approval number:
BMWF-66.009/0113-II/10b/2010).
The animals were randomly divided into 4 groups and
treated over a period of 12 weeks. Chemopreventive sub-
stances were added to a commercial rodent diet (C1000,
Altromin, Lage, Germany) as follows: 37.5 mg/kg chow
of TQ (274666, Sigma Aldrich) referred to as TQ-low
(n=13) and 375 mg/kg chow of TQ referred to as TQ-
high (n=16). 200 mg/kg chow piroxicam (P5654, Sigma-
Aldrich) was used as a positive control (n=15) [40,41].
Mice fed the diet alone served as a negative control
(n=17). Mice gaining less than 1.5 g of weight were ex-
cluded for analysis, as the chemopreventive substance
was taken up through the diet. Mice with breast cancer,
which is associated with the APCMin phenotype [42],
were euthanized and excluded from analysis. At week 9
of treatment mice underwent colonoscopy. Briefly, mice
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and xylazine, the colonoscope (Karl Storz, Tuttlingen,
Germany) connected to an airpump (Eheim, Deizau,
Germany) was inserted and the colon inflated [43].
During insertion and withdrawal of the colonoscope
up to 3 cm the number of polyps was determined in
real-time using a standard monitor and a video was
recorded. Mice were euthanized, the intestine was
dissected, flushed with PBS and 10% neutral buffered
formalin, and coiled up to a Swiss roll [44]. Prior to
paraffin embedding the intestine was fixed in neutral
buffered formalin for 24 h.
Histology, immunohistochemical analysis, and apoptosis
Serial tissue sections (4 μm) were H&E stained and ana-
lyzed by an expert pathologist (G.O.) who was blinded
for the treatment group. Polyp number, localization
(small intestine, colon), size (small < 0.3 mm; medium
0.3 – 1 mm; large polyp > 1 mm), and tumor grade (ad-
enoma; adenocarcinoma – here defined by the pene-
tration of the muscularis mucosae) were assessed [45].
Apoptosis was determined using the DeadEndTM Fluoro-
metric TUNEL System (G3250, Promega, Mannheim,
Germany). For visualization of nuclei and mounting
Vectashield® Mounting Medium with DAPI (H-1200;
Vector Laboratories, Burlingame, CA) was used and
samples were analyzed by confocal microscopy (LSM 5
exciter; Zeiss Germany).
Immunohistochemical staining was performed on
paraffin-embedded mouse intestine using antibodies
against β-catenin, Ki-67, c-myc and isotype specific
(anti-mouse/anti-rabbit) biotinylated secondary antibody
and standard staining procedures (details for antibodies
see Additional file 6: Table S1). Slides were dried, de-
waxed in xylene and rehydrated using a decreasing alco-
hol series. After blocking of endogenous peroxidase with
15% H202 in methanol, antigen retrieval was performed
in 10 mM citrate buffer, pH 6. Subsequently, slides
were blocked in 2% horse serum, 3% BSA in TRIS buffer
and endogenous IgG was blocked with Vector M.O.M.
Blocking Reagent (MKB-2213, Vector Laboratories).
Primary antibodies were incubated at 4°C overnight,
followed by biotinylated secondary antibody and avidin-
biotin-HRP complex (Vectastain ABC Kit, PK-6100;
Vector Laboratories). Staining was visualized using 3,3′-
diaminobenzidine (32750; Fluka) and nuclear coun-
terstaining was performed using hematoxylin. Slides
were dehydrated and embedded in Histofluid (6900002;
Marienfeld, Lauda Koenigshofen, Germany). Images were
recorded at 40× to 400× magnification using an Olympus
BH-2 microscope and an Olympus E330 digital camera.
Immunoreactivity was independently scored by two in-
vestigators. A standardized immunoreactivity scoring
system was modified to evaluate both the intensity ofimmunohistochemical staining and the proportion of cells
stained [46]. The staining intensity was classified into 0
(no staining), 1+ (weak), 2+ (moderate), 3+ (strong) and
the percentage of positive cells was recorded (0-100%),
resulting in a highest value of 300. Total counts were di-
vided by 25 to reach a maximum immunoreactivity score
(IRS) of 12, to be comparable to other publications using
a scoring system reaching a maximum of 12 [46]. IRS was
calculated for small polyps, large polyps and normal mu-
cosa of 6 different fields of view (FoV). C-myc staining
was evaluated by scoring the overall staining intensity per
polyp (n=16) as follows: negative (0), weakly (1+) or mo-
derately positive (2+).
Cell culture and reagents
The human colon cancer cell lines (DLD1, HCT116,
HT29, LoVo, and RKO), obtained from ATCC, were cul-
tured in IMDM (Gibco/Invitrogen) supplemented with
10% FBS (Biochrom, Berlin, Germany) and Penicillin-
Streptomycin solution (Gibco). The normal diploid hu-
man colon epithelial cell line HCEC (1CT) [47], a kind
gift from Jerry W. Shay, were cultured as previously de-
scribed [48]. Cells were incubated at 5% CO2, 37°C and
a relative humidity of 95%. Cells were treated with 10–
30 μM TQ (Sigma-Aldrich; 274666) and/or 30 μM PI3K
inhibitor LY294002 (9901; NEB) or 30 μM MEK1/2 in-
hibitor UO126 (9903; NEB) for indicated times.
Immunocytochemistry
Fluorescence immunocytochemistry was performed using
antibodies against p-GSK-3β and GSK-3β. Cells were
fixed, permeabilized, blocked and incubated with the pri-
mary antibody overnight at 4°C. For protein visualization
secondary AlexaFluor 488 antibody was used (Additional
file 6: Table S1). Nuclear counterstaining was performed
using Vectashield mounting medium with DAPI. Images
were scanned 400x magnification on a LSM 700 (Zeiss).
Annexin V/propidium iodide staining
1.5×105 RKO cells were seeded in a 6-well plate and
grown for 24 h. Cells were treated with 0–120 μM TQ
for 24 h or 5 μg/ml Actinomycin D (positive control) for
16 h and processed for Annexin V-FITC/propidium io-
dide (PI) staining according to the manufacturer’s proto-
col (eBioscience, BMS500FI). Annexin/PI positive cells
were measured with a Cell Lab Quanta SC Flow Cytome-
ter (Beckman Coulter) and analyzed with Quanta Analysis
software.
Cell viability assay
1.5×104 cells/well were seeded in a 96-well microtiter
plate and grown for 24 h. After a 24 h-treatment with
0–500 μM TQ, cells were incubated for 3 h with 0.5
mg/mL MTT (Sigma, M5655). The cells were subjected
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crystals. The intensity of the solubilized crystals was mea-
sured colorimetrically at 570 nm (Anthos 2010). Each
measurement was performed in biological quadruplicates.
Western blotting
Cells were rinsed with PBS, lysed in ice-cold RIPA buf-
fer, and centrifuged. The protein concentration was de-
termined via Bradford assay and equal protein amounts
(25 μg) were boiled in SDS gel sample buffer. Proteins
were separated by SDS–PAGE and immunoblotted onto
a PVDF membrane. Nuclear and cytoplasmic separation
was carried out as published elsewhere [49]. Membranous
and cytoplasmic separation was performed as described
by Howard et al. [50]. Primary antibodies were used
as follows: β-catenin, p-GSK-3β (Ser9), GSK-3β, c-myc,
p-ERK1/2 (Thr202/Tyr204), ERK1/2, p-Akt (Ser473), Akt,
α-tubulin, Na-K-ATPase, and fibrillarin (Additional file 6:
Table S1). Bands were visualized with anti-rabbit or anti-
mouse IRDye coupled antibodies and scanned on Odyssey
imager (LI-COR). Densitometry was done with ImageJ
1.45 (http://rsb.info.nih.gov/ij/).
Quantitative real time-PCR
Total RNA was isolated with TRIZOL reagent (Biorad)
and was reverse transcribed to cDNA using the Ther-
moscript RT-PCR System (11146–024; Invitrogen) ac-
cording to the manufacturer’s protocols. Quantitative
real time-PCR was carried out in duplicates using Fast
SYBR Green Master Mix (AB; 4385612) and c-myc pri-
mers (Additional file 6: Table S2). Data were normal-
ized to two endogenous controls GAPDH and β-actin
(QIAGEN). Relative expression levels of the transcripts
were calculated using the comparative CT method [51].
Statistics
Statistical analysis was performed using SPSS software
version 17.0. Polyp number, size, and the number of
apoptotic cells (TUNEL assay) were analyzed using uni-
variate analysis of variance (ANOVA). Results were cor-
rected by Dunnett (2-sided). Paired T-test was used to
analyze the number of apoptotic cells in the normal mu-
cosa compared to neoplastic tissue within one group.
Immunohistochemistry data for β-catenin, Ki-67 and c-
myc staining were analyzed using ANOVA. Results were
corrected by Dunnett (2-sided). To investigate the addi-
tive or synergistic nature of the effects of TQ and PI3K-
inhibitor on GSK-3β dephosphorylation the expected ef-
fects under the assumption of additivity were compared
to the actual effects measured in the double treatment
experiments. Since the effects are measured as propor-
tions, an additive nature of effects means that the ex-
pected double effect is the product of the single effects.
This product was calculated for each experiment andpoint in time and compared to the measured effect of
the double treatment by calculating the difference. The
resulting differences are reported for all experiments.
The mean and the standard deviation of the differences
were calculated for 2 h and 4 h points in time. Paired
T-tests were performed to test the null-hypotheses of
the mean differences being zero. p-values were consi-
dered as statistical significant if less than 0.05 (*p<0.05;
**p<0.01; ***p<0.001). Data are expressed by mean and
the 95% confidence interval for the mean (95% CI) or
mean and standard deviation.Additional files
Additional file 1: Figure S1. Average weight curves [g] of female
(A) and male (B) APCMin mice treated with TQ-low (nfemale=8, nmale=5
dashed line), TQ-high (nfemale=10 nmale=6 , dots), piroxicam (nfemale=11,
nmale=4 dot-dashed line) or left untreated (nfemale=12, nmale=5 , line).
Representative H&E images of tumors with different size: (I) <0.3 mm/
small, (II) 0.3-1 mm/medium, (III) >1 mm/large; 40x (C). Average food
intake in grams per mouse a day for each treatment group (D). H&E
images of the two adenocarcinomas, defined by penetration of the
muscularis mucosae, (arrows) found in the small intestine in the TQ-low
(I) and TQ-high (II) treated group; 100× (E).
Additional file 2: Figure S2. Colonoscopy and small intestinal tumor
number. Number of polyps/mouse detected during colonoscopy after 9
weeks of treatment, reaching 2–3 cm into the colon (A). Representative
images of normal mucosa (I) and polyps of different size (II-IV) are shown
(B). For TQ-low (n=14) and piroxicam (n=14) a significantly reduced
number of polyps compared to untreated (n=17) mice was found via
colonoscopy. For TQ-high (n=17) a trend for reduction of polyps was
seen. Every dot represents the number of polyps of a single mouse.
*p<0.05; ANOVA, Dunnett 2-sided. Total number of polyps in the SI of
APCMin mice (C). Bars show mean number (± SD) of SI polyps/mouse.
Piroxicam decreased the total number of SI polyps. For TQ-high there
was a trend for reduction of total SI polyps. ***p<0.001; ANOVA, Dunnett
2-sided.
Additional file 3: Figure S3. Proliferation. Ki-67 IRS (A) calculation for
villi, crypts and polyps (n=8 each, 4 mice) of untreated (B), piroxicam (C),
TQ-low (D) and TQ-high (E) treated APCMin mice. Bar graphs show mean
Ki-67 IRSs (± SD). High dose TQ lowered the amount of Ki-67 positive
cells in the villi compared to control samples, for low dose TQ there was
a trend to that effect (A). Representative images of Ki-67 staining in the
small intestine (B-E); upper left panel: normal mucosa; upper right panel:
polyp; lower panel: magnification of a single villus. Panel F shows the
negative control sample where the primary antibody was omitted (F).
*p<0.05; ANOVA, Dunnett, 2-sided was used to compare the different
treatment groups to the control group. Magnification: 100× (top panel),
400× (bottom panel).
Additional file 4: Figure S4. MTT assay. TQ exerts different effects on
cell viability in cancer cell lines having various mutational backgrounds.
Colon cancer cells and 1CT normal diploid human colon epithelial cells
were incubated with TQ at different concentrations in quadruplicates for
24 h. The absorbance values (relative OD), expressed as means, compared
to untreated cells were measured by MTT assay and IC50 concentrations
were calculated (A). TQ does not exert its effect on the p-ERK1/2 and
p-AKT1 (Ser473) pathway, but inhibition of MEK1/2 with the compound
UO126 at 30 μM abrogated p-ERK1/2 phosphorylation (Thr202/Tyr204)
between 30’ and 12 h and reduced to a much lower extent p-AKT
(Ser473), shown for whole cell lysates of RKO cells (B and D). Colon
cancer cell lines RKO and HT29 were treated with 30 μM TQ for indicated
times or left untreated (control). C-myc transcript levels stay constant
upon TQ treatment. Relative mRNA expression levels of c-myc were
calculated with GAPDH and β-actin as endogenous controls using
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Additional file 5: Figure S5. Annexin V/propidium iodide staining. RKO
cells were treated with increasing concentrations of TQ for 24 h (A-E),
with 5 μg/ml actinomycin D (positive control) for 16 h (F) or with the
DMSO (solvent for TQ) for 24 h (G). The number of viable (lower left
quadrant), early apoptotic (lower right quadrant), apoptotic (upper right
quadrant) and dead cells (upper left quadrant) was measured on a Cell
Lab Quanta SC Flow Cytometer and calculated with the Quanta Analysis
software (H). With increasing TQ concentrations the number of apoptotic
and dead cells is enriched.
Additional file 6: Table S1. Antibody list; *Immunohistochemistry;
**Immunocytochemistry. Table S2. qRT-PCR primer list.
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